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Disruption of Protein-Membrane Binding
and Identification of Small-Molecule Inhibitors
of Coagulation Factor VIII
membrane interactions are essential in many biological
pathways and processes, such as the blood coagulation
cascade [8]. Protein/membrane interactions localize
critical protein factors and their associated activities
both spatially and temporally, and they can be tightly
P. Clint Spiegel,1,3 Shari M. Kaiser,2,3
Julian A. Simon,4,5 and Barry L. Stoddard3,*
1Graduate Program in Biomolecular Structure
and Design
2 Graduate Program in Molecular and Cellular
Biology regulated through the transient presentation of unique
membrane compositions on cell surfaces that are thenUniversity of Washington
Seattle, Washington 98195 recognized and bound by specific protein ligands [9].
The interaction of many of the coagulation proteins3 Division of Basic Sciences
Mailstop A3-025 with the membrane surfaces of activated platelets (Fig-
ure 1) at the site of a vascular injury leads to a dramatic4 Division of Clinical Research
5 Division of Human Biology increase in their activity [10–12]. In the absence of these
membrane surfaces (which contain a significant per-Mailstop D2-100
1100 Fairview Avenue, North centage of phosphatidylserine [PS], as well as phospha-
tidylethanolamine [PE] and phosphatidylcholine [PC]),Fred Hutchinson Cancer Research Center
Seattle, Washington 98109 most coagulation enzymes exhibit negligible activity on
a biologically relevant time scale [8]. The serine prote-
ases involved in blood coagulation interact with these
platelet surfaces either through highly conserved do-Summary
mains containing -carboxyglutamic acid (Gla) residues,
and/or via recruitment into complexes with specificFactor VIII is a critical member of the blood coagula-
platelet binding protein cofactors (either factor V or fac-tion cascade. It binds to the membrane surfaces of
tor VIII) [10, 11]. These latter proteins associate withactivated platelets at the site of vascular injury via a
the membrane surfaces of activated platelets via highlyhighly specific interaction between factor VIII’s car-
homologous carboxy-terminal domains (termed the C1boxy-terminal C2 domain and their phosphatidylser-
and C2 domains). These domains are members of theine-rich lipid bilayer. We have identified small-mole-
discoidin protein family, a diverse group of related pro-cule inhibitors of factor VIII’s membrane binding
tein domains that mediates a wide variety of proteinactivity that have IC50 values as low as 2.5 M. This
binding interactions [13]. Disruption of the membraneinteraction is approximately 103-fold tighter than that
association of the procoagulant clotting factors V and/of free o-phospho-L-serine. These compounds also
or VIII results in failure to maintain proper hemostasisinhibit factor VIII-dependent activation of factor X, in-
[14, 15]. The presence of exposed PS in the activateddicating that disruption of membrane lipid binding
platelet membranes is crucial for binding and functionleads to inhibition of the intrinsic coagulation pathway.
of these proteins.The tightest binding inhibitor is specific and does not
Thromboembolic diseases are a major cause of mor-prevent membrane binding by the closely related co-
tality worldwide [16–18]. Traditional antithromboticagulation factor V. These results indicate that this and
treatments mostly consist of low-molecular weight hep-related compounds may be used as leads to develop
arins as well as inhibitors of vitamin K epoxide reductasenovel antithrombotic agents.
(VKOR), such as coumarin [19, 20]. Both of these antico-
agulant families display a range of undesirable clinical
Introduction side effects stemming from narrow dose-response win-
dows and/or nonspecific target interactions, thereby im-
High-throughput screening (HTS) strategies are com- parting risks of side effects that make them problema-
monly employed to discover small molecules that inhibit tic for long-term use [18]. Safer and more effective
potential drug targets [1, 2]. Most of the current targets treatments for various thromboembolic diseases are
for drug discovery fall into two categories: G protein- therefore desired [17]. Many of the anticoagulation drug
coupled receptors (GPCRs, 45%) and enzyme active candidates under current development are specific in-
sites (28%) [3, 4]. Additional forms of molecular sites hibitors of one of the serine proteases (particularly factor
and interactions, such as enzyme allosteric sites [5, 6] VIIa, factor Xa, and thrombin) from the cascade (Figure
and protein-protein complexes [7], are also under scru- 1). These enzymes represent three of approximately 176
tiny for inhibitor development. To date, there have been unique serine proteases encoded within the human ge-
no published reports indicating the use of HTS to inhibit nome [21].
protein cofactor/lipid membrane interactions. This is Recently, antithrombotic “proof of principle” experi-
due primarily to the nonspecific nature of many such ments have been directed against factor VIII, which re-
binding processes and the limited number of structural cruits one of the serine proteases from the coagulation
studies of peripheral binding of proteins to membrane cascade (factor IXa) into an active complex on platelet
surfaces. However, highly specific protein cofactor/lipid surfaces (Figure 1). A monoclonal antibody, mAb-LE2E9,
partially inactivates factor VIII through binding to its C1
and C2 domains. A recombinant form of this antibody*Correspondence: bstoddar@fhcrc.org
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Figure 1. Factor VIII and the Coagulation Cascade
(A) The blood coagulation cascade consists of two pathways (extrinsic and intrinsic) that are initiated by the exposure of tissue factor (TF)
or phosphatidylserine (PS) groups of activated platelet membranes to circulating protein factors, respectively. Factor VIII is a large plasma
glycoprotein that acts as an initiator and regulator of the intrinsic pathway [44]. Upon proteolytic activation by either factor Xa or thrombin,
activated factor VIII (FVIIIa) dissociates from von Willebrand factor (VWF), associates with the factor IXa serine protease, and directs the
localization of the resulting complex to the membrane surface of activated platelets, via an interaction with its C-terminal C2 domain (structure
in inset) [45]. The membrane-bound factor VIIIa/factor IXa complex functions to proteolytically activate factor X [12], which then activates
thrombin (factor II).
(B) Domain structure of factor VIII. Factor VIII is synthesized as a single polypeptide chain of 2,332 residues [11]. Based on sequence homology,
factor VIII has the domain structure A1-A2-B-A3-C1-C2, where the A domains are homologous to the copper binding protein ceruloplasmin,
the C domains are homologous to the discoidin fold family (structure in inset), and the unique B domain has no known homologs [46–48].
Membrane association is primarily accomplished through the C2 domain; its deletion completely abrogates binding of factor VIII to platelet
surfaces [49]. Crystal structures of the factor VIII C2 domain (inset) indicate its probable membrane binding surface [30, 31].
was tested in a murine venous thrombosis model and of the intrinsic blood coagulation pathway, as measured
by reduced activation of the factor X serine protease.demonstrated potent antithrombotic properties without
bleeding complications [22, 23]. The most potent of these compounds were shown to
bind directly to the C2 domain, and to not interact non-In vivo data demonstrating that inhibition of factor VIII
cofactor function leads to reduction thrombosis, as well specifically with the membranes themselves, or with
either the closely related coagulation factor V or theas biochemical studies that indicate the existence of a
defined membrane binding surface on the factor VIII C2 unrelated membrane binding enzyme phospholipase A2.
domain, imply that factor VIII might be a viable drug
target for the development of novel anticoagulants [17]. Results
Additionally, factor VIII has one of the shortest half-lives
(10 hr) and lowest serum concentrations (0.3 nM) in Purification and Characterization of the
Recombinant Factor VIII C2 Domaincirculation of any of the coagulation factors, increasing
its attractiveness as a drug target [12]. The factor VIII C2 domain consists of residues Ser2173
to Tyr2332 and is the domain responsible for binding toWe have devised an enzyme-linked immunoadsor-
bent assay (ELISA)-based, high-throughput screen to PS-containing membrane surfaces of activated platelets
(Figure 1). Purified samples of bacterially expressed,identify inhibitors of the factor VIII C2 domain’s mem-
brane binding activity. Starting with a screen of 10,000 recombinant C2 domain (Figure 2A) were analyzed by
circular dichroism (CD) and MALDI mass spectrometrystructurally diverse small molecules, we isolated com-
pounds that inhibit the ability of the factor VIII C2 do- to determine that the protein was properly folded and
of the correct mass (18.6 kDa). The C2 domain wasmain, as well as the full-length protein, to bind phospho-
lipid surfaces similar in composition to activated platelet characterized in a PS-based ELISA experiment and was
shown to bind specifically to immobilized lipid surfacesmembranes. Improved analogs of the initial hits were
selected from an expanded chemical library consisting containing PS (Figure 2A). Similar experiments against
membranes containing PC resulted in negligible binding.of over one million compounds. Inhibitors of factor VIII
membrane binding exhibit a dose-dependent inhibition To indicate whether the C2-PS interaction could be spe-
Identification of Factor VIII Inhibitors
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Figure 2. Characterization of Recombinant
Factor VIII C2 Domain
(A) Membrane binding ELISA for the C2 do-
main. The C2 domain binds specifically to
the PS surface, while it only binds negligible
amounts to PC surfaces (dark circle: PS sur-
face, light circle: PC surface). The inset is
an SDS-PAGE gel showing the purification
of recombinant C2 domain using a bacterial
expression system.
(B) Titration of O-phosphatidylserine (OPS;
chemical structure shown in inset) with the
C2 domain in membrane binding ELISA.
cifically disrupted, we titrated the soluble headgroup of brane binding assay (Figure 4). The IC50 values for these
compounds span a range of approximately 5–60 M.PS (o-phospho-L-serine) with the C2 domain prior to
incubation with the PS-coated plates. As expected, we Of these hits, the more weakly inhibiting compounds
display few structural and/or physicochemical similari-observed a dose-dependent inhibition of PS associa-
tion, yielding an IC50 value of approximately 2 mM (Fig- ties. However, the two hits with the lowest IC50 concen-
tration values (compound numbers 3 and 4 in Figuresure 2B).
3 and 4) are related, both containing a tricyclic N-aryl-
bromofurfurylidine-thiazolidinedione core.
High-Throughput Screening and Validation of Hits
To screen and identify compounds that inhibit the mem-
brane association of the factor VIII C2 domain, we modi- Chemical Variation and Analysis of Inhibitor Hits
Commercially available compounds from the extendedfied the ELISA-based assay described above, preincu-
bating the C2 domain with a set of compounds prior to Chembridge collection that were structurally similar to
hits 3, 4, and 9 were analyzed to further test the struc-its addition to PS-immobilized plates. The Chembridge
DIVERSet 10,000 compound library was screened in ture-activity relationship of their inhibitory properties.
Analogs of the initial hits that exhibited the strongestgroups of 5 compounds per well. The entire screen was
performed in duplicate with positive and negative con- inhibition of C2 domain membrane binding are shown
in Figure 5A. In the case of compounds 3 and 4, theretrols on each plate to decrease the hit rate due to false
positives. Top scoring hits were subsequently deconvo- is a strong correlation between patterns of substitutions
on the furan ring and inhibitory activity. When the bro-luted to determine the identity of each individual inhibi-
tory compound from the initial mixtures. The screen mine atom is substituted with either an iodine atom
or another halogenated, aromatic six-membered ringresulted in ten compounds that inhibit the C2-PS inter-
action completely at an initial concentration of 160 M (compounds 31, 32, and 41), the IC50 is lower (i.e., tighter
binding and stronger inhibition). Alternatively, when the(Figure 3).
The IC50 values of the ten best compounds from the bromine atom is replaced with a hydrogen atom, inhibi-
tor activity is significantly reduced (structure not shown).screen were determined by titrating variable concentra-
tions of compounds against the C2 domain in the mem- Variations in the phenyl moiety of compound 9 indicate
Figure 3. Chemical Structures of the Ten
Best Hits
Each of the chemical structures with their
corresponding IC50 values based on the mem-
brane binding ELISA are grouped into three
categories: weak (compounds 1, 2, 5, 6, and
8 had an IC50  20 M), moderate (com-
pounds 7 and 10 had an IC50 between 10 and
20 M), and strong (compounds 3, 4, and 9
had an IC50  10 M).
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Figure 4. Titration Curves for the Ten Best
Hits in the PS-Based ELISA
(A) Compounds 1–5 in the PS-based ELISA
using the C2 domain (open circle: 1, closed
triangle: 2, open diamond: 3, closed circle: 4,
closed diamond: 5).
(B) Compounds 6–10 in the PS-based ELISA
using the C2 domain (open circle: 6, closed
triangle: 7, open square: 8, closed diamond:
9, closed circle: 10). Binding curves were cal-
culated by nonlinear regression with the pro-
gram GraphPad Prism.
that altering the position of either the nitro group or the Inhibition Studies with Recombinant,
Full-Length Factor VIIIchloride atoms does not significantly affect the activity
of this class of compounds. Of the analogs tested, com- To determine whether the inhibitory activity of these
compounds toward the factor VIII C2 domain corre-pound 32 in our screen (Figure 5A; Chembridge
#8047577) displayed the lowest IC50 for inhibition of sponds to similar inhibition of full-length factor VIII, we
performed titrations of compounds with the PS-basedmembrane binding by the factor VIII C2 domain (2.4 M).
ELISA experiment using a recombinant, full-length fac-This compound contains a dichlorophenyl substitution
tor VIIIa heterodimer [25]. The most active compoundsfor the furanyl bromine atom in compound 3 from the
from C2 domain inhibition assays (3, 31, 32, 4, 41, 9, 91,original screen.
and 92) were tested to determine their corresponding
IC50 values. For those compounds related to hits 3 and
4 in the original screen (which are themselves closelyControl Experiments: The Inhibitors Act
related to each other as described above), the IC50 valuesSpecifically on Factor VIII
for inhibition of membrane binding by either the C2 do-To validate that the most potent compounds in this study
main or the full-length factor VIIIa heterodimer are simi-were specifically binding to the factor VIII C2 domain
lar. Compound 32, which exhibits the most effectiveand thereby inhibiting its membrane binding interaction,
inhibition of the C2 domain, is also the best inhibitor ofsix control experiments were conducted. First, the ability
factor VIIIa (Figure 5A). The third hit to be varied andof the immobilized membranes to support protein bind-
tested (compound 9 and its cousins) displays lower cor-ing in the ELISA assay was shown to be unimpaired
relations between the IC50 values against the free C2after their direct incubation with the individual com-
domain and the full-length factor VIIIa construct. Con-pounds and a secondary wash step (data not shown).
served patterns of physicochemical properties that ap-Second, the inhibitors were also shown to inhibit factor
pear important for inhibitor activity are most consistentVIII-dependent activation of factor X, under conditions
for those compounds that exhibit the tightest bindingin which phospholipids were in vast excess of inhibitors
in membrane binding inhibition assays.(see results below). Third, the best inhibitors from the
study were shown to bind directly to the C2 domain by
fluorescence spectroscopy, with equilibrium dissocia- Inhibition of Factor X Activation
tion constants (KD) that are similar to the observed IC50 The screens described above were developed and con-
values from membrane binding inhibition curves (39.9, ducted based on the hypothesis that inhibitors of factor
32.8, and 28.8 M for compounds 3, 32, and 9, respec- VIII membrane binding should also inhibit the ability of
tively). Fourth, to validate that the best compounds were factor VIII to act as an activating cofactor in the intrinsic
specifically blocking the membrane binding surface and coagulation pathway. In order to address this hypothe-
activity of factor VIII rather than simply inducing protein sis, we conducted an in vitro assay to monitor the rate
aggregation, the solution behavior of the protein was of factor VIII-dependent activation of factor X as a func-
assayed by size-exclusion chromatography and dy- tion of the presence and concentration of the small-
namic light scattering after incubation with compounds molecule inhibitors of factor VIII lipid binding described
and was found to be unchanged (data not shown). Fi- above. In the presence of calcium ions and phospholip-
nally, the best inhibitors of factor VIII membrane binding ids containing PS, factor X is activated by factor IXa
were tested and shown to be incapable of blocking (a process sometimes called the tenase reaction). This
membrane binding activity of either the closely related reaction is greatly enhanced by the presence of factor
homolog factor V (which displays 40% sequence identify VIII. Utilizing a chromogenic substrate that is specific
and identical phospholipid binding specificity with fac- for factor Xa, one can measure the rate of factor X
tor VIII) (Figure 5B) or the unrelated membrane binding activation to factor Xa. Antibodies specific to the C2
enzyme cytosolic phospholipase A2 (cPLA2). This latter domain of factor VIII have been shown previously to
protein binds neutral phospholipid surfaces with a struc- inhibit the ability of factor X to become activated. The
tural membrane binding region that also is termed a “C2” strongest inhibitors described above were titrated (20–
domain, but is completely unrelated to the C2 domain of 1.25 M) against recombinant factor VIII in this assay
to determine the IC50 values for the inhibition of factorfactor VIII [24].
Identification of Factor VIII Inhibitors
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Figure 5. Chemical Structures of Variations to Compounds 3, 4, and 9
(A) Chemical structures of compounds 3, 31, 32, 4, 41, 9, 91, and 92 are shown with their associated IC50 values for the inhibition of the C2
domain and factor VIII ELISA and for the inhibition of the factor X activation assay. Structural variations and associated IC50 values indicate
a structure-activity relationship for the mode of binding to the C2 domain. Substitutions at the bromine atom in compounds similar to 3 and
4 have effects of the potency. Larger or more hydrophobic substitutions increase the inhibitory activity.
(B) Relative inhibition of factor VIII and factor V by various inhibitors from the panel above, all measured at 20 M concentration.
X activation. The titrations for compounds 3, 31, 32, 9, tion. To ensure that the compounds were not acting
directly on factor X in this assay, a control was done91, and 92 approach complete inhibition of the factor X
activation at 20M, again with IC50 values that are similar for each in which the reaction mix was spiked with an
excess of preactivated factor Xa (1 g/ml). All com-to those measured for inhibition of factor VIIIa mem-
brane binding (Figures 5 and 6). Of these compounds, pounds had little or no effect on the intrinsic ability of
factor Xa to cleave its chromogenic substrate.number 32 (the most effective inhibitor of membrane
binding) is also the most effective inhibitor of factor X Finally, a panel of five compounds (3, 4, 9, 41, and
32) were tested for their ability to inhibit the factor VIII-activation, with an IC50 value of 2.1 M. In contrast,
compounds 4 and 41 never approach complete inhibi- dependent activation of factor X by using platelet-
enriched human serum as a source of membranes, totion of the activation of factor X, only inhibiting at ap-
proximately 35%–40% at 20 M compound concentra- test whether their inhibitory properties would be re-
Chemistry & Biology
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Figure 6. Inhibitory Effect of Compounds on
Factor X Activation
(A) Titrations of compounds 3 (closed circle),
31 (open circle), and 32 (square).
(B) Titrations of compounds 4 (closed circle)
and 41 (open circle).
(C) Titrations of compounds 9 (closed circle),
91 (open circle), and 92 (square).
(D) Relative inhibition of factor X activation
by factor VIII.
(E) Relative inhibition of factor X activation in
the presence of purified lipids (L) and platelet-
rich plasma (P). Activation of factor X in the
absence of added compounds, as described
in the Experimental Procedures, gives a sig-
nal in the assay defined as 100%. All com-
pounds demonstrate inhibition of factor VIII
activity in this assay. At 10 M concentra-
tions, one compound [3] displays a reduced
potency in the presence of platelet-rich
plasma; the remainder display similar inhibi-
tion properties. Compound 32 is potent under
either condition.
duced in the presence of physiological plasma compo- Factor VIII is an attractive drug target for at least two
nents and when using platelet surfaces as a substrate, reasons. First, it possesses the lowest plasma half-life
rather than purified lipids. These experiments were per- and concentration (10 hr and 0.3 nM, respectively) of all
formed by using the protocol of Ahmad et al. [26], with the coagulation factors in the intrinsic pathway, corre-
the exception that platelets were not gel purified away sponding to a lower target concentration for therapeutic
from serum components, but rather were added as inhibition [12]. Second, it utilizes a structural protein fold
platelet-rich plasma in order to more closely mimic for membrane binding (a discoidin domain) that is far
in vivo circulation. Platelets were counted by using a more rare in the human genome and also more highly
hemocytometer; their concentration in the experiment diversified at the level of primary sequence and tertiary
was 2 107/ml. At 10M concentrations, all compounds structure than is the serine protease family (the source
demonstrated inhibition of the factor X activation in the of anticoagulant targets thrombin, factor VIIa and factor
presence of platelet-rich serum. Compound 3 exhibited Xa) [13, 21]. The structural conservation of serine prote-
a signficantly reduced activity, while the remaining four ases (176 significant, unique representatives in the hu-
retained potency. As in previous studies with purified man genome identifiable by BLAST searches, compared
components, compound 32 was the most effective, to 23 identifiable homologs of the factor VIII C2 discoidin
demonstrating almost complete inhibition of factor X domain) is a well-documented source of undesirable
activation. (Figure 6D). nonspecific pharmacological effects in clinical applica-
tions.
Based on the structural and biochemical data describ-Discussion
ing the mechanism of membrane binding for the factor
VIII C2 domain [27–29], it seemed plausible that potentThe basic principles of this work are straightforward.
inhibitors can be developed that target a specific regionFactor VIII binds to specific anionic membrane surfaces
of the C2 domain. The crystal structures of the C2 do-of activated platelets, at the site of a vascular injury,
main alone and in complex with an inhibitory antibodyand then acts to recruit additional activated clotting
derived from a hemophilia A patient indicate a bindingfactors (particularly factor IXa) to that location (Figure
cleft at one end of the molecule that consists of solvent-1). Factor VIII binds to these membrane surfaces via
exposed hydrophobic residues and positively chargedinteractions between its C-terminal C2 domain and the
basic residues [30, 31]. Additional biochemical dataplatelets’ PS-rich phospholipid bilayer. We predicted
suggest that this region is primarily responsible for bind-that inhibition of this interaction by a small molecule
ing to activated platelet surfaces based on mutationalwould lead to inhibition of steps in the coagulation cas-
results [27, 29]. Moreover, membrane binding experi-cade that are dependent on factor VIII, such as activation
ments indicate that factor VIII binds preferentially to theof the serine protease factor X. We are able to identify
L-isomer of PS, further supporting a specific interactioninhibitors of the factor VIII-membrane interaction and
between factor VIII and membrane surfaces on activateddemonstrated that such compounds can prevent factor
VIII from participating in the activation of factor X. platelets [32]. Lastly, mutational data suggest that per-
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participate in membrane insertion are more strongly
conserved.
The combination of these results indicates that the
discovery of small molecules against the membrane as-
sociation of the factor VIII C2 domain could lead to
the development of potent antithrombotic therapeutics.
Additionally, the use of simple, single domain subunits
(such as the C2 domain) of large, multidomain protein
complexes (factor VIII) as targets in high- throughput
screening (HTS) experiments may lead to more rapid
assay development and could circumvent cost prohibi-
tive experiments. In many cases, the development of
HTS protocols is often hindered by the ability to produce
enough reagents for use in a large-scale assay. The
results presented here indicate that inhibitors targeting
simple and easily produced subunits can directly trans-
late to function against the entire macromolecular
complex.
Although the compounds described in this paper (par-
ticularly compound 32, with an in vitro IC50 value of 2M)
display reasonable inhibition of the membrane binding
and factor X activation activities of purified factor VIII
in the presence of synthetic PS-rich lipids or activated
platelets, the compounds in their current form display
relatively poor inhibition of factor VIII-dependent proco-
agulant activity in whole plasma (i.e., against endoge-
nous factor VIII). One possible explanation for this obser-
Figure 7. Docked Model of Compound 32 Bound to the Factor VIII vation is that binding of these compounds is competitive
C2 Domain against von Willebrand factor, which is present in whole
Compound 32 was docked to the membrane binding surface of the plasma and the circulation in vast excess of factor VIII,
C2 domain by using protein AUTODOCK [50]. The conformation and is thought to bind to factor VIII by interacting with
shown in the figure corresponds to the best (lowest) calculated
its membrane binding surface [29, 33–38]. If this is true,energy in a collection of 50 separate runs and also represents a
then the further optimization of the compounds reportedcluster of several independent hits that converged to similar bound
here, into inhibitors with low nanomolar affinities, mayconformations from those runs. The interactions between com-
pound and protein domain in this docked model are described in be necessary before significant in vivo anticoagulant
the Discussion. activities are realized.
In conclusion, the use of a competition assay based
on disrupting the interaction between a nonenzymatic
turbation of the C2 domain’s membrane binding surface protein cofactor and its affinity for the hydrophilic head-
is associated with deficiencies in factor VIII activity [33]. group of a specific phospholipid surface leads to a new
The observation that the highest affinity inhibitor of area for the discovery of small-molecule inhibitors. Our
factor VIII membrane binding does not prevent similar results indicate that, through the use of high-throughput
binding by the closely related factor V provides impor- screening techniques, we have determined a novel
tant confirmation of specificity as well as insight into method for discovering small-molecule inhibitors of pro-
potential modes of its interaction. Computational dock- tein/membrane interactions, leading to the identification
ing experiments with compound 32 against the crystallo- of a class of compounds that display inhibition of the
graphic model of the factor VIII C2 domain indicate that procoagulant function of factor VIII.
the compound may bind to a pair of pockets flanked by
the hydrophobic  hairpin turns of its membrane binding
surface (Figure 7). In this model, the two six-membered Significance
phenyl rings are both partially buried in these pockets,
with their trifluoro and dichloro substituents in contact To the best of our knowledge, this study provides the
first example of using drug discovery methods, includ-with protein backbone and side chain atoms. The entire
compound is wrapped around an aromatic side chain ing high-throughput compound library screening, to
inhibit a specific protein-membrane binding interac-(Phe2196) that separates the two pockets. This binding
mode agrees well with the effect of chemical substitu- tion. While such a strategy may be limited to protein-
membrane interactions that are highly specific, it rep-ents on the inhibitory IC50 values described above, par-
ticularly the contribution of the phenyl rings and their resents a significant departure from the development
of enzyme inhibitors and/or receptor antagonists. Thechemical substituents to overall affinity. Two residues
in this region that might contact the bound inhibitor interaction targeted in this study (the binding of factor
VIII to the surface of activated platelets) represents a(Phe2196 and Ala2201) are poorly conserved in factor
V and are instead a lysine and an aspartic acid, respec- novel strategy for the design of small compounds with
anticoagulant properties. The development of a classtively. In contrast, surrounding protein side chains that
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BSA-TBS, was then incubated for 60 min at 37C with shaking.of anticoagulants that do not target serine proteases
Plates were rinsed three times with TBS between each incubation.such as factor X may provide a useful adjunct to the
Subsequent to the C2 domain incubation, 100 l mAb ESH-8 dilutedcurrent classes of compounds now under study. A
1:1000 in BSA-TBS was added. 100 l of an alkaline phosphatase
significant question remaining to be answered is (AP)-conjugated goat anti-mouse antibody was then added. Factor
whether further improvement in affinity and specificity VIII and/or the C2 domain that had bound to the plate was detected
by the addition of p-nitrophenyl phosphate (pNPP), followed byover that reported in this paper can be realized, and
absorbance measurements at 405 nm with a microplate reader.whether those improvements will translate into signifi-
cant anticoagulant activity in vivo.
Compound Library Screening
The library of 10,000 compounds was diluted from 20 mM stocksExperimental Procedures
in dimethyl sulfoxide (DMSO) to groups of 5 compounds each at
750 M per compound in water. For high-throughput assay pur-Reagents
poses, the C2 domain diluted in TBS was incubated with each mix-Monoclonal antibody (mAb) ESH-8 was purchased from American
ture of drugs at 200 M for 30 min at room temperature. BSA wasDiagnostica, Inc., and an Fc-specific, goat anti-mouse IgG that is
subsequently added to a concentration of 2% (w/v). The resultingalkaline phosphatase (AP)-conjugated was purchased from Sigma.
mixture was then added to the ELISA plates at the C2 domainMaxisorb plates (96-well) were purchased from Nunc, o-phosphati-
incubation step. Subsequent development of binding assays wasdyl-L-serine was purchased from Avanti Polar Lipids, Inc., and bo-
carried out as described above, and deconvolutions from initial hitsvine serum albumin (fraction V powder) and p-nitrophenyl phosphate
and titrations were performed similarly.(pNPP) were purchased from Sigma. Recombinant, full-length factor
VIIIa heterodimer was a generous gift from Y.H. Kim (Suwon, South
Factor X Activation AssayKorea). The COAMATIC factor X activation assay kit is a product of
A commercially available chromogenic assay that measures the rateChromogenix that was purchased through Diapharma Group, Inc.
of factor X activation was used according to the manufacturer’sThe DIVERSet compound library and subsequent individual variants
instructions to measure inhibition of the cofactor function of factorof initial compound hits from that library were purchased from
VIII [41]. When factor VIII is added to a reaction mixture containingChembridge Corporation. Factor V and anti-factor V antibody (clone
thrombin, factor IXa, excess factor X, calcium, phospholipids, andHFV-1) were purchased from American Diagnostica, Inc. Cytosolic
a chromogenic substrate specific for factor Xa (S-2765), a measurephospholipase A2 (cPLA2) was provided by the Michael Gelb lab
of factor X activation can be detected and is linearly related to factor(University of Washington Department of Chemistry), who also con-
VIII activity. Full-length, recombinant factor VIIIa heterodimer wasducted inhibition assays with that enzyme for this study.
diluted to 1 g/ml in sample buffer (25 mM Tris-HCl [pH 7.9] and
1% [w/v] bovine serum albumin) and incubated with various drugFactor VIII C2 Domain Expression/Purification
concentrations. The different factor VIII mixtures were then used asA construct containing the factor VIII C2 domain (residues 2171–
a substitute for plasma samples containing the appropriate concen-2332) was subcloned into a pET15b plasmid (Novagen) by using the
tration of factor VIII. Proteolytic cleavage of the chromogenic sub-restriction enzymes NdeI and BamHI (New England Biolabs) and
strate was measured with a microplate spectrophotometer at antransformed into the AD-494 cell line (Novagen) cotransformed with
absorbance of 405 nm. Reactions were stopped by the addition ofa plasmid encoding for rare tRNAs (RIL, Novagen). Five milliliter
20% (v/v) glacial acetic acid.cultures were grown overnight from a single colony at 37C in Luria
The assay was also performed using platelet-rich plasma (ob-Broth (LB) medium containing 35 mg/L chloramphenicol, 25 mg/L
tained as a gift from the clinical division of the Hutchinson Center) inkanamycin, and 100 mg/L ampicillin. One liter cultures were inocu-
place of purified phospholipids, in order to determine if the inhibitorslated with 5 ml overnight cultures and grown to an OD600 of 0.8–1.0.
retain potency in a system that more closely resembles the bloodC2 domain expression was induced by the addition of 1 mM isopro-
circulation. After low-speed centrifugation to remove erythrocytes,pyl-thio--D-galactosidase (IPTG). Inductions were grown for 16–20
the platelet count was determined by using a hemocytometer, andhr at 16C with shaking.
platelets were added to a concentration of 2  107/ml, correspond-Cells were lysed by sonication in 300 mM NaCl, 20 mM Tris-
ing to the platelet concentration typically used in similar assaysHCl (pH 7.0), 10 mM imidazole, 0.01% (v/v) Triton X-100, 100 M
described by Ahmad et al. [26]. Purified platelets were not used inphenylmethylsulfonyl fluoride (PMSF), and 2.5% (v/v) glycerol. Ly-
this assay in order to more closely mimic natural human plasma.sates were centrifuged at 16,000 rpm in an SS-34 rotor (Sorvall) for
Compound Binding to C2 Domain30 min. The supernatant was applied to TALON metal affinity resin
Fluorescence binding experiments to demonstrate direct binding of(Clontech) at 4C for 1.5–2.0 hr. The protein-resin slurry was applied
optimal compounds to the C2 domain and thereby determine anto a gravity-flow column. The resin was washed with 20 column
equlibrium dissociation constant (KD) were performed on a Perkinvolumes of 300 mM NaCl, 20 mM Tris-HCl (pH 7.0), 10 mM imidazole,
Elmer LS50 B Luminescence spectrometer. The excitation wave-and 2.5% (v/v) glycerol and subsequently washed with 20 column
length was 278 nm, with bandwidths of 5 nm for excitation and 5volumes of 150 mM NaCl, 20 mM Tris-HCl (pH 7.0), 10 mM imidazole,
nm for emission; fluorescence was monitored from 310 nm to 400and 2.5% (v/v) glycerol. The C2 domain was eluted in 150 mM NaCl,
nm. Fluorescence titrations were performed by sequentially adding20 mM Tris-HCl (pH 8.0), 150 mM imidazole, and 2.5% (v/v) glycerol
0.5–5 l of a concentrated ligand solution to 3000 l of the C2and subsequently dialyzed into 150 mM NaCl, 20 mM Tris-HCl (pH
domain solution. The fluorescence signal and ligand concentration7.4), and 2.5% (v/v) glycerol. The histidine tag was subsequently
were adjusted for the effects of dilution. Fluorescence quenchingremoved with biotinylated thrombin according to the manufacturer’s
was calculated from Q  (F 	 F0)/F0 where F is the intensity of theprotocol (Novagen). The C2 domain was further purified by using a
fluorescent signal corrected for dilution and F0 is the signal in theheparin affinity column (Applied Biosystems). The purified C2 do-
absence of ligand. Dissociation constants were calculated by fittingmain was concentrated to 5 mg/ml, flash frozen in liquid nitrogen,
the quenching data to the equation:and placed at –80C for storage.
Q  Qmax/(1 
 KD/[Ligand]), (1)
Phosphatidylserine Binding ELISA
The interaction between factor VIII and PS was measured by using where Qmax is the maximal quenching in the absence of ligand and
KD is the apparent dissociation constant for the ligand.an enzyme-linked immunoadsorbent assay (ELISA) that was
adapted from previously described methods [39, 40]. Maxisorb
plates (96-well) (Nunc) were incubated with 100 l 5 g/ml PS dis- Phospholipase A2 Membrane Binding
and Enzyme Activity Assaysolved in methanol and dried overnight at room temperature. Plates
were then blocked with 200 l of 2% (w/v) bovine serum albumin Recombinant cytosolic group IV phospholipase A2 with a C-terminal
6-histidine tag was prepared as described [42]. The assay with thein Tris-buffered saline (BSA-TBS). 100 l factor VIII or its C2 domain
(or full-length factor V in control experiments), diluted to 50 nM in fluorimetric substrate Glu (the umbeliferryl ester of -linolenic acid)
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has been described previously [43]. Briefly, assay buffer consists interactions and approaches to prevent their action. Haemo-
philia 8, 1–11.of 50 mM Tris (pH 8.0), 150 mM NaCl, 0.2 mM EGTA, 0.5 mM CaCl2,
30% (v/v) glycerol, and 0.024% (w/v) Triton X-100. A total of 2.8l Glu 15. Spiegel, P.C., Jr., and Stoddard, B.L. (2002). Optimization of
factor VIII replacement therapy: can structural studies help in(1 mM in DMSO was added to 1 ml of assay buffer in a fluorescence
cuvette. Excitation was at 375 nm, and emission was monitored at evading antibody inhibitors? Br. J. Haematol. 119, 310–322.
16. Tripodi, A. (2003). Levels of coagulation factors and venous460 nm with stirring at room temperature. The assay was initiated
by the addition of 0.48 g of cytosolic phospholipase A2, and the thromboembolism. Haematologica 88, 705–711.
17. Ruef, J., and Katus, H.A. (2003). New antithrombotic drugs onemission was followed for 2 min. Inhibitor was added at various
concentrations to assay buffer prior to the addition of enzyme. the horizon. Expert Opin. Investig. Drugs 12, 781–797.
18. Hyers, T.M. (2003). Management of venous thromboembolism:
past, present, and future. Arch. Intern. Med. 163, 759–768.Acknowledgments
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